DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lapatinib
Lapatinib
TYKERB Decreases in Left Ventricular Ejection Fraction (LVEF) Have Been Reported
Combining Paclitaxel and Lapatinib As Second-Line Treatment for Patients with Metastatic Transitional Cell Carcinoma: a Case Series
HER2-Positive Male Breast Cancer: an Update
Lapatinib Has Been Associated with Hepatotoxicity
Fasting Potentiates the Anticancer Activity of Tyrosine Kinase Inhibitors by Strengthening MAPK Signaling Inhibition
Identification of Candidate Repurposable Drugs to Combat COVID-19 Using a Signature-Based Approach
Votrient, INN-Pazopanib
BC Cancer Benefit Drug List September 2021
Genome-Wide DNA Copy Number Predictors of Lapatinib Sensitivity in Tumor-Derived Cell Lines
Activity of Lapatinib Is Independent of EGFR Expression Level in HER2-Overexpressing Breast Cancer Cells
T-DM1 As a New Treatment Option for Patients with Metastatic HER2-Positive Breast Cancer in Clinical Practice
Changing the Destiny of HER2 Expressing Solid Tumors
5Th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5)5
Enhanced PI3K P110a Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a P110a-Selective PI3K Inhibitor
Ontogeny and Vulnerabilities of Lapatinib Drug-Tolerant Persisters in HER2+ Breast Cancer
Trastuzumab Emtansine: a Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
Clinical Pharmacology and Biopharmaceutics Review(S)
125427Orig1s000
Top View
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
(Trastuzumab-DM1) for Treatment of HER-2 Positive Malignancies
MEK Inhibitors for the Treatment of Non-Small Cell Lung Cancer
In Vivo Assessment of Potential for UGT-Inhibition-Based Drug-Drug Interaction Between Sorafenib and Tapentadol
Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites Ana Carolina C
Small Molecule Tyrosine Kinase Inhibitors of Erbb2/HER2/Neu in the Treatment of Aggressive Breast Cancer
Preparation of Antibodies and Development of an Enzyme-Linked
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits
A Study of Neratinib Plus Capecitabine Versus
Tyrosine Kinase Inhibitor Family of Drugs As Prospective Targeted Therapy for COVID-19 Based on in Silico and 3D-Human Vascular Lung Model Studies
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
VOTRIENT (Pazopanib) Tablets Gastrointestinal Perforation Or Fistula
Tyverb, INN-Lapatinib
Genetic Modifiers of EGFR Dependence in Non-Small Cell Lung Cancer
In Gastric Cancer Positive for MET Amplification
Synergistic Proapoptotic Effects of the Two Tyrosine Kinase Inhibitors Pazopanib and Lapatinib on Multiple Carcinoma Cell Lines
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients With